TVTX
$27.76
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Travere Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases in the United States. The company's products include FILSPARI (sparsentan), a once-daily, o...
Recent News
Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli
MIRM completes enrollment in phase III EXPAND study of Livmarli for treating additional rare cholestatic liver diseases. Top-line data due in Q4 2026.
Piper Sandler Increases Target Price for Travere Therapeutics (TVTX)
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the 10 most shorted biotech stocks to buy according to hedge funds. On February 19, Travere Therapeutics Inc. (NASDAQ:TVTX) released the fourth quarter earnings report. The company registered U.S. net product sales figures of $126.6 million for the quarter, relative to $73.5 million during the fourth quarter of […]
Travere Therapeutics, Inc. (TVTX): A Bull Case Theory
We came across a bullish thesis on Travere Therapeutics, Inc. on HalfBakedInnovations’s Substack by Biotech Distilled. In this article, we will summarize the bulls’ thesis on TVTX. Travere Therapeutics, Inc.’s share was trading at $30.07 as of February 9th. TVTX’s forward P/E was 26.32 respectively according to Yahoo Finance. Travere Therapeutics (TVTX) is a biotech company focused on rare kidney and metabolic diseases, with its lead asset FILSPARI (sparsentan) targeting IgA Nephropathy (IgAN) [
Travere Therapeutics (TVTX) Reports 144% Annual Growth in Filspari Sales for 2025
Travere Therapeutics Inc. (NASDAQ:TVTX) is one of the best stocks for beginners with little money in 2026. On February 19, Travere Therapeutics reported earnings for Q4 and full-year 2025, highlighting significant growth for its flagship medication, Filspari. The company achieved quarterly net product sales of $126.6 million and a full-year total of $410.5 million, with […]
A Look At Travere Therapeutics (TVTX) Valuation After Q4 Earnings Beat And FILSPARI Regulatory Progress
Travere Therapeutics (TVTX) is back in focus after Q4 2025 results topped earnings expectations, supported by record demand for FILSPARI, with investors also weighing recent FDA approvals and late stage pipeline progress. See our latest analysis for Travere Therapeutics. Travere’s recent updates around FILSPARI approvals, the pending FSGS decision and progress in pegtibatinase appear to have influenced trading, with a 7 day share price return of 9.24% and a 1 year total shareholder return of...